Skip to main content

Table 3 Comparative pharmacokinetic study of satranidazole drug and test formulation

From: Satranidazole-loaded chitosan/locust bean gum/xanthan gum polysaccharide composite multiunit pellets for colon targeting: in vitro–in vivo investigation

Pharmacokinetic parameters

Raw drug

Test formulation

p-value

Cmax (mcg. /ml.)

Mean

51.07

Mean

35.02

0.00001(S)

 ± S.D

1.21

 ± S.D

3.91

tmax (h)

Mean

2.50

Mean

2.50

1(NS)

 ± S.D

0.55

 ± S.D

0.55

AUC0-t (mcg. h/ml.)

Mean

381.95

Mean

312.00

0.00088(S)

 ± S.D

18.61

 ± S.D

31.66

AUC0-∞ (mcg. h/ml.)

Mean

395.64

Mean

333.46

0.00089(S)

 ± S.D

18.20

 ± S.D

34.29

kel (h−1)

Mean

0.143

Mean

0.121

0.000012(S)

 ± S.D

0.006

 ± S.D

0.004

t1/2 (h)

Mean

4.86

Mean

5.75

0.00001(S)

 ± S.D

0.19

 ± S.D

0.17

Relative bioavailability (%)

100%

81.69%

Log-transformed (LN) relative bioavailability (%)

100%

96.60%

  1. *Cmax Maximum plasma concentration, tmax Time to maximum plasma concentration, AUC0-t The area under plasma concentration time curve, AUC0-inf The area under plasma concentration time curve 0 to infinity, t1/2 Elimination half-life, Kel Elimination rate constant
  2. *Significant and nonsignificant value indicates by S and NS